ICON plc (NASDAQ:ICLR) is expected to report third quarter earnings results, after market close, on Wednesday 21st October 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 1.53 per share.
Looking ahead, the full year income are expected at $ 6.27 per share on the revenues of $ 2718.70 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2,650.00 million ~ $ 2,750.00 million, where as bottomline are predicted in a range of $ 6.00 ~ $ 6.50 per share
Click Here For More Historical Outlooks Of ICON plc
Previous Quarter Performance
ICON plc disclosed income for the second quarter of $ 1.20 per share, from the revenue of $ 620.23 million. The quarterly earnings 28.99 percent compared with the same quarter last year. Wall street analysts are predicting, ICLR to report 2Q20 income of $ 1.10 per share from revenue of $ 598.77 million. The bottom line results beat street analysts by $ 0.1 or 9.09 percent, at the same time, top line results outshined analysts by $ 21.46 million or 3.58 percent.
Stock Performance
Shares of ICON plc traded low $ -0.67 or -0.33 percent on Tuesday, reaching $ 203.33 with volume of 130.40 thousand shares. ICON plc has traded high as $ 206.54 and has cracked $ 202.49 on the downward trend
The closing price of $ 203.33, representing a 95.63 % increase from the 52 week low of $ 104.28 and a 5.24 % decrease over the 52 week high of $ 215.29.
The company has a market capital of $ 10.70 billion and is part of the Healthcare sector and Diagnostics & Research industry.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The companys clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services.
